E-64d – 10 mg

Brand:
Cayman
CAS:
88321-09-9
Storage:
-20
UN-No:
Non-Hazardous - /

E-64d is an irreversible, membrane-permeable inhibitor of lysosomal and cytosolic cysteine proteases and has diverse biological activities.{18463,14249,18464,49542} It is a synthetic analog of E-64 (Item No. 10007963) and prodrug form of E-64c (Item No. 10007964) that inhibits calpain and the cysteine proteases cathepsins F, -K, -B, -H, and -L.{18463, 58182} E-64d (20-200 µM) induces cell cycle arrest at the G2/M phase in A431 human epidermoid carcinoma cells.{14249} It inhibits protease-resistant prion protein accumulation in scrapie-infected neuroblastoma cells with an IC50 value of 0.5 µM.{18464} E-64d also inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein incorporation into pseudotyped vesicular stomatitis virus (VSV) particles in Vero cells, an effect that is reduced by expression of the serine protease TMPRSS2.{49542}  

 

SKU: - Category:

Description

A protease inhibitor with diverse biological activities; inhibits calpain and the cysteine proteases cathepsins F, -K, -B, -H, and -L; induces cell cycle arrest at the G2/M phase in A431 human epidermoid carcinoma cells from 20-200 µM; inhibits protease-resistant prion protein accumulation in scrapie-infected neuroblastoma cells (IC50 = 0.5 µM); inhibits SARS-CoV and SARS-CoV-2 surface glycoprotein incorporation into pseudotyped VSV particles in Vero cells


Formal name: 3-[[[(1S)-3-methyl-1[[(3S-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-2S-oxiranecarboxylic acid, ethyl ester

Synonyms:  Aloxistatin|E-64c ethyl ester|EP 453|EST|Loxistatin|NSC 694281

Molecular weight: 342.4

CAS: 88321-09-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals|Protease Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cell Biology|Proteolysis|Lysosomal Proteases||Research Area|Immunology & Inflammation|Pulmonary Diseases|COVID-19||Research Area|Immunology & Inflammation|Pulmonary Diseases|MERS||Research Area|Infectious Disease|Viral Diseases|Coronaviruses||Research Area|Neuroscience|Neurodegenerative Disorders|Prion Disease